0000000000937359

AUTHOR

Anne Marie Bouvier

showing 22 related works from this author

Rural–urban inequalities in detection rates of colorectal tumours in the population

2011

Abstract Background Because few data are available on this topic, we investigated the influence of geographical determinants on colorectal adenoma detection and cancer incidence rates. Methods Between 1990 and 1999, 6220 Cote d’Or inhabitants (France) were first-diagnosed with a colorectal adenoma, and 2389 with an invasive adenocarcinoma. The impact of the rural–urban place of residence and of a physician location in municipalities on adenoma and cancer detection rates was studied using Poisson regression. Results World-standardized adenoma detection rate was significantly higher in urban areas (102 [95%CI: 97–107]) than in rural areas (78 [95%CI: 72–84]). The impact of the absence of phys…

MaleRural PopulationOncologymedicine.medical_specialtyUrban PopulationAdenomaColorectal cancerPopulationColorectal adenomasymbols.namesakeInternal medicinemedicineHumansMass ScreeningPoisson regressioneducationRetrospective Studieseducation.field_of_studyHepatologybusiness.industryIncidenceGastroenterologyPrimary care physicianHealth Status DisparitiesMiddle Agedmedicine.diseaseSurvival RateSocioeconomic FactorsPopulation SurveillancesymbolsAdenocarcinomaFemaleFranceRural areaColorectal NeoplasmsbusinessDemographyDigestive and Liver Disease
researchProduct

Patterns of recurrence of obstructing colon cancers after surgery for cure: a population-based study.

2013

Aim Little is known about patterns of recurrence in obstructing colon cancer (OCC) at a population level. The aim of this study was to determine the risk of recurrence following potentially curative surgery in OCC compared with that in uncomplicated colon cancer (CC). Method Data were obtained from the population-based digestive cancer registry of Burgundy (France). Local and distant failure rates were calculated using actuarial methods. A multivariate analysis was performed using a Cox model. Results Obstructing colon cancer represented 8.5% of all colon cancers resected with curative intent (n = 3375). The 5-year cumulative local recurrence rate was 14.2% for OCC and 7.6% for nonobstructi…

Malemedicine.medical_specialtyMultivariate analysisColorectal cancerPopulationDisease-Free SurvivalColonic DiseasesRisk FactorsmedicineHumansRegistriesRisk factoreducationMass screeningAgedProportional Hazards Modelseducation.field_of_studybusiness.industryProportional hazards modelHazard ratioCarcinomaGastroenterologyAge FactorsMiddle Agedmedicine.diseasePrognosisSurgeryRelative riskColonic NeoplasmsMultivariate AnalysisFemaleNeoplasm Recurrence LocalbusinessIntestinal ObstructionColorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
researchProduct

Endocrine tumours: epidemiology of malignant digestive neuroendocrine tumours.

2013

Little is known about patients with malignant digestive neuroendocrine tumours (MD-NETs). Although their incidence is increasing, MD-NETs remain a rare cancer, representing 1% of digestive cancers. Most MD-NETs are well-differentiated. MD-NET poorly differentiated carcinomas account for 20% of cases on average. Anatomical localisation of MD-NETs varied according to geographic region. Stage at diagnosis and prognosis for patients with MD-NETs in the general population are considerably worse than often reported from small hospital case series. Prognosis varies with tumour differentiation, anatomic site and histological subtype. There are significant differences in survival from MD-NETs among …

Oncologymedicine.medical_specialtyeducation.field_of_studybusiness.industryEndocrinology Diabetes and MetabolismPoorly differentiatedIncidence (epidemiology)PopulationGeneral MedicineRare cancerSmall hospitalNeuroendocrine TumorsEndocrinologyEndocrinologyInternal medicineEpidemiologyEndocrine Gland NeoplasmsmedicineEndocrine systemAnimalsHumansbusinesseducationDigestive cancerGastrointestinal NeoplasmsEuropean journal of endocrinology
researchProduct

The influence of geographical access to health care and material deprivation on colorectal cancer survival: Evidence from France and England

2014

International audience; This article investigates the influence of distance to health care and material deprivation on cancer survival for patients diagnosed with a colorectal cancer between 1997 and 2004 in France and England. This population-based study included all cases of colorectal cancer diagnosed between 1997 and 2004 in 3 cancer registries in France and 1 cancer registry in England (N=40,613). After adjustment for material deprivation, travel times in England were no longer significantly associated with survival. In France patients living between 20 and 90min from the nearest cancer unit tended to have a poorer survival, although this was not statistically significant. In England, …

MaleHealth (social science)Colorectal cancerGeography Planning and DevelopmentPopulationcolorectal cancer[SDV.CAN]Life Sciences [q-bio]/CancersurvivalHealth Services AccessibilityHealth services[SDV.CAN] Life Sciences [q-bio]/CancerHealth caremedicineHumansRegistrieseducationmaterial deprivationAgedTraveleducation.field_of_studyGeographybusiness.industrytravel timesPublic Health Environmental and Occupational HealthCancerCancer survivalMiddle Agedmedicine.diseaseHealth care accessibility3. Good healthCancer registryEnglandFemaleFranceColorectal NeoplasmsbusinessDemographyHealth & Place
researchProduct

Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.

2016

IF 10.383; International audience; OBJECTIVES: Cancer may be a complication of inflammatory bowel disease (IBD) or its treatment. In elderly onset IBD patients the risk of malignancy is of particular concern. We studied this risk in a population-based cohort of elderly onset IBD patients.METHODS: In a French population-based cohort, we identified 844 patients aged >60 years at IBD diagnosis from 1988 to 2006, including 370 Crohn's disease (CD) and 474 ulcerative colitis (UC). We compared incidence of cancer among IBD patients with that observed in the French Network of population-based Cancer Registries (FRANCIM). Confidence interval (CI) was estimated assuming a Poisson-specific law for ra…

MESH: CarcinomaMaleNonmelanoma Skin-CancerInflammatory bowel disease0302 clinical medicineAdrenal Cortex HormonesAzathioprineMESH: IncidenceAge of OnsetAged 80 and overeducation.field_of_studyMESH: Middle AgedRheumatoid-ArthritisIncidenceGastroenterologyMESH: Follow-Up StudiesMESH: Anti-Inflammatory Agents Non-Steroidal3. Good health030220 oncology & carcinogenesisCohort030211 gastroenterology & hepatology[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: Immunosuppressive Agentsmedicine.medical_specialtyMESH: Age of OnsetMESH: Colitis Ulcerativedigestive systemMESH: Adrenal Cortex Hormones03 medical and health sciencesIntestinal NeoplasmsHumansCrohns-DiseaseeducationMESH: Intestinal NeoplasmsMESH: Protective FactorsMESH: AzathioprineAgedRetrospective StudiesMESH: HumansMESH: Crohn DiseaseTumor Necrosis Factor-alphaMESH: Retrospective Studiesmedicine.diseaseMESH: Inflammatory Bowel DiseasesInflammatory Bowel Diseasesdigestive system diseasesLymphoproliferative DisordersMethotrexateMESH: Tumor Necrosis Factor-alphaColitis UlcerativeComplicationMESH: FemaleProspective Observational CohortTime FactorsMESH: RegistriesMESH: Proportional Hazards ModelsMaintenance TherapyMESH: Aged 80 and overMESH: Lymphoproliferative DisordersCrohn DiseaseMESH: Risk FactorsRisk FactorsNeoplasmsMESH: NeoplasmsRegistriesUlcerative-ColitisMesalamineMESH: AgedIncidence (epidemiology)Anti-Inflammatory Agents Non-SteroidalMetaanalysisMiddle AgedhumanitiesMESH: MethotrexateFemaleFranceFrench PopulationColorectal NeoplasmsImmunosuppressive AgentsMESH: Myeloproliferative DisordersPopulationColorectal-CancerIncreased RiskInternal medicinemedicineProportional Hazards ModelsMyeloproliferative DisordersHepatologybusiness.industryMESH: Time FactorsCarcinomaCancerRetrospective cohort study[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: MesalamineProtective FactorsMESH: MaleMESH: FranceAge of onsetbusinessMESH: Colorectal NeoplasmsFollow-Up StudiesThe American journal of gastroenterology
researchProduct

Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil–based chem…

2014

Background & Aims Patients with colorectal tumors with microsatellite instability (MSI) have better prognoses than patients with tumors without MSI, but have a poor response to 5-fluorouracil–based chemotherapy. A dominant-negative form of heat shock protein (HSP)110 (HSP110DE9) expressed by cancer cells with MSI, via exon skipping caused by somatic deletions in the T 17 intron repeat, sensitizes the cells to 5-fluorouracil and oxaliplatin. We investigated whether HSP110 T 17 could be used to identify patients with colorectal cancer who would benefit from adjuvant chemotherapy with 5-fluorouracil and oxaliplatin. Methods We characterized the interaction between HSP110 and HSP110DE9 using su…

MaleModels MolecularOrganoplatinum CompoundsColorectal cancermedicine.medical_treatment[SDV]Life Sciences [q-bio]Leucovorin0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsHSP110 Heat-Shock ProteinsComputingMilieux_MISCELLANEOUSColectomySequence Deletion0303 health sciencesGastroenterologyPrimary tumor3. Good healthOxaliplatinTreatment OutcomeFluorouracilChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleMicrosatellite InstabilityFluorouracilColorectal Neoplasmsmedicine.drugBlotting WesternAntineoplastic AgentsBiology03 medical and health sciencesCell Line TumormedicineBiomarkers TumorHumans030304 developmental biologyAgedRetrospective StudiesChemotherapyHepatologyBase SequenceMicrosatellite instabilityCancerSurface Plasmon Resonancemedicine.diseaseMolecular biologySurvival AnalysisIntronsOxaliplatinCancer cellCancer researchFollow-Up StudiesGastroenterology
researchProduct

Management and prognosis of pancreatic cancer over a 30-year period.

2009

BACKGROUND: The aim of this study was to report on changes in the diagnostic assessment, patterns of care and survival over time for pancreatic cancers. METHODS: A total of 2986 cases of pancreatic cancer from the Digestive Cancer Registry of Burgundy (France) over a 30-year period (1976–2005) were considered. Non-conditional logistic regressions were carried out to identify the factors associated with resection for cure and with the use of chemotherapy. A multivariate relative survival analysis was carried out. RESULTS: Diagnostic procedures have changed. Ultrasonography and computed tomography progressively have become the major diagnostic procedures. There was a slight improvement in sta…

MaleCancer Researchmedicine.medical_specialtyMultivariate analysisPancreatic diseasemedicine.medical_treatmentpancreatic cancerGastroenterologysurvivalstage at diagnosisInternal medicinePancreatic cancerClinical StudiesmedicineHumanscancer registryStage (cooking)Diagnostic Techniques and ProceduresAgedNeoplasm StagingAged 80 and overChemotherapyRelative survivalbusiness.industryCancerMiddle Agedmedicine.diseasePrognosisSurgeryCancer registryPancreatic NeoplasmsLogistic ModelsOncologyMultivariate AnalysisFemalebusinessmanagementBritish journal of cancer
researchProduct

Epidemiology and prognosis of synchronous colorectal cancers

2008

Abstract Background The aim of this population-based study was to report on the incidence, treatment and prognosis of synchronous colorectal carcinomas. Methods Data were obtained from the population-based cancer registry of Burgundy. Results Between 1976 and 2004, 15 562 colorectal cancers were diagnosed. Some 3·8 per cent of patients had synchronous colorectal cancers. The risk of having synchronous cancers was higher in men (odds ratio (OR) 1·41 (95 per cent confidence interval (c.i.) 1·19 to 1·68)), when associated adenomas were present (OR 2·02 (95 per cent c.i. 1·69 to 2·41)), when there were adenomatous remnants on pathological examination (OR 2·10 (95 per cent c.i. 1·73 to 2·55)) an…

Malemedicine.medical_specialtyAdenomaColorectal cancerPopulationGastroenterologyNeoplasms Multiple PrimaryRisk FactorsInternal medicinemedicineHumanseducationAgedRetrospective Studieseducation.field_of_studyRelative survivalbusiness.industryIncidenceIncidence (epidemiology)CancerOdds ratioMiddle AgedPrognosismedicine.diseaseSurgeryCancer registryFemaleSurgeryFranceColorectal NeoplasmsbusinessBritish Journal of Surgery
researchProduct

Comorbidities Alone Do Not Explain the Undertreatment of Colorectal Cancer in Older Adults: A French Population-Based Study

2011

OBJECTIVES: To investigate the influence of comorbidities on treatment modalities of colorectal cancer according to the age of patients and French recommendations. DESIGN: Population-based study SETTING: French Digestive Cancer Registry, Burgundy. PARTICIPANTS: Two thousand nine hundred twenty-one incident colorectal cancers diagnosed between 2004 and 2007. MEASUREMENTS: The independent influence of comorbidities (recorded according to the Charlson index) on treatment was analyzed using multivariate logistic regressions controlling for age, sex, and their interaction. RESULTS: The association between comorbidities and resection for cure was significant only in patients younger than 75 (P in…

Geriatricsmedicine.medical_specialtyeducation.field_of_studyChemotherapybusiness.industryColorectal cancermedicine.medical_treatmentPopulationCancermedicine.diseaseComorbidityCancer registrySurgeryRadiation therapyInternal medicinemedicineGeriatrics and GerontologybusinesseducationJournal of the American Geriatrics Society
researchProduct

Disparités du taux de détection des adénomes colorectaux en fonction du lieu de domicile et de la distance aux médecins en Côte-d’Or, entre 1990 et 1…

2010

EpidemiologyPublic Health Environmental and Occupational HealthRevue d'Épidémiologie et de Santé Publique
researchProduct

Adjuvant treatments for gastric cancer: From practice guidelines to clinical practice

2013

Abstract Background For gastric cancers, the benefits of adjuvant radiochemotherapy and of perioperative chemotherapy have been demonstrated since 2001 and 2006 respectively. The aim of this study was to evaluate the diffusion of adjuvant treatments in a French population. Methods 334 incident gastric cancers UICC Stage IB, II, III or IVM0 resected for cure and recorded in the Burgundy digestive cancer registry were retrospectively included. Patients were classified as having received an effective adjuvant treatment if they had been treated by adjuvant radiochemotherapy since 2001 or perioperative chemotherapy since 2006. Results The proportion of patients treated with an effective adjuvant…

MaleOncologymedicine.medical_specialtymedicine.medical_treatmentPopulationStomach NeoplasmsInternal medicineCarcinomaHumansMedicineRegistrieseducationAgedRetrospective StudiesAged 80 and overeducation.field_of_studyHepatologybusiness.industryCarcinomaGastroenterologyCancerRetrospective cohort studyChemoradiotherapy AdjuvantMiddle Agedmedicine.diseaseCancer registryRadiation therapyRegimenLogistic ModelsTreatment OutcomeChemotherapy AdjuvantMultivariate AnalysisPractice Guidelines as TopicFemaleFranceGuideline AdherencebusinessAdjuvantDigestive and Liver Disease
researchProduct

Estimation of National Colorectal-Cancer Incidence Using Claims Databases

2012

Background.The aim of the study was to assess the accuracy of the colorectal-cancer incidence estimated from administrative data.Methods.We selected potential incident colorectal-cancer cases in 2004-2005 French administrative data, using two alternative algorithms. The first was based only on diagnostic and procedure codes, whereas the second considered the past history of the patient. Results of both methods were assessed against two corresponding local cancer registries, acting as “gold standards.” We then constructed a multivariable regression model to estimate the corrected total number of incident colorectal-cancer cases from the whole national administrative database.Results.The firs…

EstimationArticle SubjectEpidemiologybusiness.industryColorectal cancerIncidence (epidemiology)lcsh:RPublic Health Environmental and Occupational HealthMEDLINElcsh:MedicineRegression analysiscomputer.software_genremedicine.diseaseCancer registryAdministrative databaseStatisticsGeneticsMedicineData miningClaims databasebusinesscomputerResearch ArticleJournal of Cancer Epidemiology
researchProduct

Epidemiology, Management, and Survival of Peritoneal Carcinomatosis from Colorectal Cancer

2015

Modern chemotherapy aims to improve long-term survival for selected patients with peritoneal carcinomatosis. Publications suggest promising results, but the spread of these new aggressive treatment strategies in the general population is not well known.The aim of this study was to draw a picture of epidemiology, management, and survival in synchronous and metachronous peritoneal carcinomatosis from colorectal cancer.The cumulative risk of metachronous peritoneal carcinomatosis was estimated in patients resected for cure. Net survival rates were calculated for synchronous and metachronous peritoneal carcinomatosis.The study was conducted with the use of the Burgundy Digestive Cancer Registry…

MaleOncologymedicine.medical_specialtyColorectal cancerPopulationAntineoplastic AgentsAdenocarcinomaInternal medicineEpidemiologymedicineCarcinomaHumansRegistrieseducationSurvival ratePeritoneal NeoplasmsAgedRetrospective Studieseducation.field_of_studybusiness.industryCarcinomaGastroenterologyRetrospective cohort studyCytoreduction Surgical ProceduresGeneral MedicinePrognosismedicine.diseaseAdenocarcinoma MucinousSurvival RateAdenocarcinomaFemaleObservational studyFrancePeritoneumColorectal NeoplasmsbusinessDiseases of the Colon & Rectum
researchProduct

Management of rectal cancers in relation to treatment guidelines: a population-based study comparing Italian and French patients

2014

Few studies have investigated rectal cancer management at the population level. We compared how rectal cancers diagnosed in Italy (2003-2005) and France (2005) were managed, and evaluated the extent to which management adhered to European guidelines.Samples of 3938 Italian and 2287 French colorectal cancer patients were randomly extracted from 8 and 12 cancer registries respectively. Rectal cancer patients (860 Italian, 559 French) were analysed. Logistic regression models estimated odds ratios (ORs) of being treated with curative intent, receiving sphincter-saving surgery, and receiving preoperative radiotherapy.Similar proportions of Italian and French patients were treated with curative …

Malemedicine.medical_specialtyPreoperative radiotherapyPopulation levelColorectal cancer[SDV]Life Sciences [q-bio]Anal CanalAdenocarcinomaLogistic regressionInternal medicinemedicineHumansComputingMilieux_MISCELLANEOUSAgedAged 80 and overHepatologybusiness.industryRectal NeoplasmsGastroenterologyCancerOdds ratioMiddle Agedmedicine.diseaseNeoadjuvant Therapy3. Good healthSurgeryCancer registryPopulation based studyItalyPractice Guidelines as TopicLymph Node ExcisionFemaleRadiotherapy AdjuvantFranceGuideline AdherencebusinessOrgan Sparing Treatments
researchProduct

Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study

2017

Background: Rare cancers pose challenges for diagnosis, treatments, and clinical decision making. Information about rare cancers is scant. The RARECARE project defined rare cancers as those with an annual incidence of less than six per 100 000 people in European Union (EU). We updated the estimates of the burden of rare cancers in Europe, their time trends in incidence and survival, and provide information about centralisation of treatments in seven European countries. Methods: We analysed data from 94 cancer registries for more than 2 million rare cancer diagnoses, to estimate European incidence and survival in 2000–07 and the corresponding time trends during 1995–2007. Incidence was calcu…

Male0301 basic medicinePathologypopulation-based registriesCancer Care Facilities; Delivery of Health Care; Europe; Female; Hospitalization; Humans; Incidence; Male; Neoplasms; Rare Diseases; Registries; Survival Rate; Oncology0302 clinical medicineNeoplasmsMedicineRegistriesmedia_commonTumors -- Treatment -- Europeeducation.field_of_studyRelative survivalIncidenceIncidence (epidemiology)RARECARE projectEuropeHospitalizationSurvival RateOncology030220 oncology & carcinogenesis/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemalemedicine.medical_specialtyHealth surveysPopulationSocio-culturaleCancer Care Facilities03 medical and health sciencesRare DiseasesSDG 3 - Good Health and Well-beingHumansmedia_common.cataloged_instanceCancer -- MortalityRisk factorEuropean unioneducationSurvival rateOncology cancer burden incidence rare cancerpopulation-based registriesrare cancers cancer registry RARECAREbusiness.industryRare cancerCancer -- Patients -- Long-term careCancer registry030104 developmental biologycancer burdenbusinessDelivery of Health CareDemographyRare disease
researchProduct

Long-term Net Survival in Patients With Colorectal Cancer in France

2013

Net survival, the survival that might occur if cancer was the only cause of death, is a major epidemiological indicator. Recent findings have shown that the classical methods used for the estimation of net survival from cancer registry data, referred as to "relative-survival methods," provided biased estimates.The aim of this study was to provide, for the first time, long-term net survival rates for colorectal cancer by using a population-based digestive cancer registry.This study is a population-based cancer registry analysis. The recently proposed unbiased nonparametric Pohar-Perme estimator was used.Overall, 14,715 colorectal cancers diagnosed between 1976 and 2005 and registered in the …

MaleOncologymedicine.medical_specialtyPathologyTime FactorsColorectal cancerStatistics NonparametricBiasInternal medicineEpidemiologymedicineHumansRegistriesSurvival rateSurvival analysisAgedNeoplasm StagingRetrospective StudiesCause of deathAged 80 and overbusiness.industryAge FactorsGastroenterologyCancerRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseSurvival AnalysisCancer registrySurvival RateFemaleFranceColorectal NeoplasmsbusinessDiseases of the Colon & Rectum
researchProduct

Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of c…

2008

The RAS-MAPK, PI (3)K signaling pathways form a network that play a central role in tumorigenesis. The BRAF, KRAS and PI3KCA genes code 3 partners of this network and have been found to be activated by mutation in colorectal cancer; these mutations lead to unrestricted cell growth. We evaluated the clinicopathological features and the prognosis of patients with activated-network colon cancers in a population-based study. A total of 586 colon adenocarcinomas were evaluated using sequencing for mutations of KRAS and PI3KCA, and allelic discrimination for mutation of BRAF. Clinicopathological characteristics were correlated to the risk of bearing a mutation of the network using logistic regres…

MaleProto-Oncogene Proteins B-rafCancer Researchmedicine.medical_specialtyClass I Phosphatidylinositol 3-KinasesColorectal cancerPopulationAdenocarcinomaBiologymedicine.disease_causeProto-Oncogene Proteins p21(ras)Phosphatidylinositol 3-KinasesProto-Oncogene ProteinsInternal medicineBiomarkers TumormedicineHumanseducationSurvival rateAgedMutationeducation.field_of_studyMicrosatellite instabilityCancermedicine.diseaseSurvival RateEndocrinologyOncologyColonic NeoplasmsMutationras ProteinsCancer researchFemaleMicrosatellite InstabilityFranceKRASMitogen-Activated Protein KinasesCarcinogenesisSignal TransductionInternational Journal of Cancer
researchProduct

A population-based study of adjuvant chemotherapy for stage-II and -III colon cancers.

2010

Summary Background Although clinical trials have demonstrated that adjuvant chemotherapy improves survival for stage-III colon cancer, the benefits remain controversial for stage-II lesions. The objective of the present study was to determine the extent to which adjuvant chemotherapy is used for patients with stage-II and -III colon cancers. Methods The study population comprised 1074 patients with stage-II and -III colon cancers diagnosed in 2000 in 12 French administrative districts and recorded in population-based cancer registries. Data were collected using a standardized procedure. Results Overall, 20.4% of patients with stage II and 61.9% with stage III received adjuvant chemotherapy.…

MaleOncologymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentPerforation (oil well)Population[SDV.CAN]Life Sciences [q-bio]/CancerAdenocarcinomaSampling Studies[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansRegistries030212 general & internal medicineStage (cooking)educationAgedAged 80 and overPatient Care TeamChemotherapyeducation.field_of_studybusiness.industryAge FactorsGastroenterologyCancerGeneral MedicineMiddle Agedmedicine.disease3. Good healthSurgeryClinical trialChemotherapy AdjuvantIntestinal Perforation030220 oncology & carcinogenesisColonic NeoplasmsMultivariate AnalysisPopulation studyFemaleFrancebusinessIntestinal Obstruction
researchProduct

Improvement in survival of metastatic colorectal cancer: Are the benefits of clinical trials reproduced in population-based studies?

2012

To describe trends in survival of non-resectable metastatic colorectal cancer (MCRC) over a 34-year period in a French population-based registry taking into account major advances in medical therapy.3804 patients with non-resectable metastatic colorectal cancer diagnosed between 1976 and 2009 were included. Three periods (1976-96, 1997-2004 and 2005-09) were considered.The proportion of patients receiving chemotherapy dramatically increased from 19% to 57% between the first two periods, then increased steadily thereafter reaching 59% during the last period (p0.001). Median relative survival increased from 5.9 months during the 1976-96 period to 10.2 months during the 1997-2004 period but, d…

MaleOncologyCancer Researchmedicine.medical_specialtyTime FactorsColorectal cancermedicine.medical_treatmentPopulationAntineoplastic AgentsPopulation basedHealth Services AccessibilityInternal medicinemedicineHumansMolecular Targeted TherapyRegistriesHealthcare DisparitieseducationAgedClinical Trials as TopicChemotherapyeducation.field_of_studyEvidence-Based MedicineMedical treatmentbusiness.industryPatient SelectionPalliative CareAge FactorsTreatment optionsMiddle Agedmedicine.diseaseSurvival AnalysisSurvival RateClinical trialTreatment OutcomeOncologyFemaleFranceDiffusion of InnovationColorectal NeoplasmsbusinessMedical therapyEuropean Journal of Cancer
researchProduct

Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases.

2008

Abstract The CpG island methylator phenotype (CIMP) is a distinct phenotype in colorectal cancer, associated with specific clinical, pathologic, and molecular features. However, most of the studies stratified methylation according to two subgroups (CIMP-High versus No-CIMP/CIMP-Low). In our study, we defined three different subgroups of methylation (No-CIMP, CIMP-Low, and CIMP-High) and evaluated the prognostic significance of methylation status on a population-based series of sporadic colon cancers. A total of 582 colon adenocarcinomas were evaluated using methylation-specific PCR for 5 markers (hMLH1, P16, MINT1, MINT2, and MINT31). No-CIMP status was defined as no methylated locus, CIMP-…

OncologyAdultMaleProto-Oncogene Proteins B-rafCancer Researchmedicine.medical_specialtyPathologyColorectal cancerPopulationBiologyAdenocarcinomamedicine.disease_causeProto-Oncogene Proteins p21(ras)Internal medicineProto-Oncogene ProteinsmedicineHumanseducationneoplasmsAgededucation.field_of_studyRelative survivalCpG Island Methylator PhenotypeMicrosatellite instabilityMethylationDNA MethylationMiddle Agedmedicine.diseasePrognosisdigestive system diseasesPhenotypeOncologyDNA methylationColonic NeoplasmsMutationras ProteinsCpG IslandsFemaleMicrosatellite InstabilityKRASCancer research
researchProduct

Patterns of adjuvant chemotherapy for stage II and III colon cancer in France and Italy

2013

European guidelines recommend adjuvant chemotherapy for stage III colon cancer but not for stage II.To determine the extent to which adjuvant chemotherapy was used in Italy and France.A common retrospective database of 2186 colon cancers diagnosed between 2003 and 2005 was analysed according to age, stage and presenting features.38.9% of patients with stage II and 64.6% with stage III received chemotherapy in Italy, 21.7% and 65.1% in France. For stage II, the association between country and chemotherapy was only significant in patients diagnosed out of emergency (ORItaly/France: 3.05 [2.12-4.37], p0.001) whereas patients diagnosed in emergency were as likely to receive chemotherapy in both…

AdultMaleOncologymedicine.medical_specialtyAdolescentAdjuvant chemotherapyColorectal cancermedicine.medical_treatmentStage iiLower riskDisease-Free SurvivalInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansIn patientStage (cooking)ChildAgedNeoplasm StagingRetrospective StudiesAged 80 and overChemotherapyHepatologybusiness.industryInfant NewbornGastroenterologyInfantMiddle Agedmedicine.diseaseCancer registryItalyChemotherapy AdjuvantChild PreschoolColonic NeoplasmsPractice Guidelines as TopicFemaleFranceGuideline AdherencebusinessDigestive and Liver Disease
researchProduct

Incidence, Presentation, and Prognosis of Small Bowel Adenocarcinoma in Patients with Small Bowel Crohn's Disease: A Prospective Observational Study.

2013

International audience; BACKGROUND:: Patients with Crohn's disease (CD) of the colon are at risk for colorectal cancer and should be screened for dysplasia and cancer of the colon. Small bowel adenocarcinoma (SBA) is a complication of small bowel CD and carries a poor prognosis. However, there is no screening test for SBA in patients with small bowel CD. The aim of this study was to assess the risk and incidence of SBA in a large prospective cohort of patients with small bowel CD and to compare it with the risk of colorectal cancer in patients with CD involving the colon, recruited in the same cohort. METHODS:: In a nationwide French cohort, 11,759 patients with CD were enrolled by 680 gast…

AdultMalemedicine.medical_specialtyColorectal cancerPopulationAdenocarcinomaGastroenterology03 medical and health sciences0302 clinical medicineCrohn DiseaseInterquartile rangeRisk Factors[ CHIM.ORGA ] Chemical Sciences/Organic chemistryInternal medicinemedicineImmunology and AllergyHumansProspective StudieseducationProspective cohort studyCrohn's diseaseeducation.field_of_studybusiness.industry[CHIM.ORGA]Chemical Sciences/Organic chemistryIncidence (epidemiology)IncidenceGastroenterologyCancerMiddle Agedmedicine.diseasePrognosisdigestive system diseasesIleal Neoplasms030220 oncology & carcinogenesisCohort030211 gastroenterology & hepatologyFemaleFrancebusinessColorectal NeoplasmsFollow-Up Studies
researchProduct